Evidence map›Paper›PMID 38117349›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2023

Sleep dysfunction associated with worse chemotherapy-induced peripheral neurotoxicity functional outcomes.

Fawaz Mayez Mahfouz, Tiffany Li, Masarra Joda, Michelle Harrison, Lisa G Horvath, Peter Grimison, Tracy King, Gavin Marx, David Goldstein, Susanna B Park

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Integrating Sleep Health Education in Cancer Care: Prevalence and Correlates of Insomnia Among Omani Patients Undergoing Chemotherapy.Journal of cancer education : the official journal of the American Association for Cancer Education · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Fawaz Mayez MahfouzBrain and Mind Centre, The University of Sydney, Camperdown, NSW, 2050, Australia.
Tiffany LiBrain and Mind Centre, The University of Sydney, Camperdown, NSW, 2050, Australia.
Masarra JodaBrain and Mind Centre, The University of Sydney, Camperdown, NSW, 2050, Australia.
Michelle HarrisonChris O'Brien Lifehouse, Camperdown, NSW, 2050, Australia.
Lisa G HorvathChris O'Brien Lifehouse, Camperdown, NSW, 2050, Australia.
Peter GrimisonChris O'Brien Lifehouse, Camperdown, NSW, 2050, Australia.
Tracy KingCancer Nursing Research Unit, The University of Sydney, Camperdown, NSW, 2050, Australia.
Gavin MarxSydney Adventist Hospital, Wahroonga, NSW, 2076, Australia.
David GoldsteinPrince of Wales Clinical School, Faculty of Medicine & Health, UNSW Sydney, Randwick, NSW, 2031, Australia.
Susanna B ParkBrain and Mind Centre, The University of Sydney, Camperdown, NSW, 2050, Australia. susanna.park@sydney.edu.au.
The University of Sydney · AUChris O’Brien Lifehouse · AUPrince of Wales Hospital · AURoyal Prince Alfred Hospital · AUSydney Adventist Hospital · AU

Funding

Cancer Institute NSW 14/TPG/1-05Cancer Institute NSW 2021/CBG0002National Health and Medical Research Council 1080521
6 · The paper itself

Abstract

purposeSleep problems are commonly reported by cancer survivors; however, knowledge of the impact of chemotherapy-induced peripheral neurotoxicity (CIPN) on sleep quality remains limited. In this study, we explored the impact of CIPN on sleep quality, as well as identified clinical characteristics associated with poor sleep quality.

methodsParticipants were assessed cross-sectionally post-neurotoxic chemotherapy. CIPN severity was graded using a range of questionnaires that assessed CIPN severity and quality of life, as well as neurological grading scales. Sleep quality was assessed using a self-rated questionnaire (Pittsburgh Sleep Quality Index, PSQI). Participants with poor sleep quality were further grouped according to whether sleep impairment was due to CIPN or other factors.

resultsAmong 77 participants who reported CIPN, 75% (n = 58) reported poor sleep quality. Of those, 41% (n = 24) reported CIPN as contributing to sleep impairment, while 59% (n = 34) reported other causes. Participants with CIPN-induced sleep impairments had higher CIPN severity across all outcome measures, as well as greater neuropathic pain (all p < 0.05). Furthermore, participants with CIPN-induced sleep impairments reported worse impact of neuropathy on physical and social functioning, as well as emotional well-being (all p < 0.05).

conclusionsParticipants with CIPN-induced poor sleep quality reported worse scores across all CIPN severity measures. This emphasises the negative impacts of CIPN symptoms on quality of life of chemotherapy-treated patients and highlights the importance of sleep quality assessment in cancer survivors.

Indexed as

Antineoplastic AgentsNeurotoxicity SyndromesSleep Wake DisordersHumansQuality of LifeSleepAntineoplastic AgentsCancer survivorsChemotherapy-induced peripheral neurotoxicity (CIPN)InsomniaSleep impairmentSleep quality

Identifiers

PMID38117349
PMCPMC10733204
OpenAlexW4390011024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.